ライフサイエンスコーパス: intravenous infusion

1 injection) and dexamethasone (20 mg oral or intravenous infusion).

2 dose of AMPH (0.1 mg/kg) was administered by intravenous infusion.

3 etermined with the use of a [1-(13)C]leucine intravenous infusion.

4 nd gave a stable aqueous system suitable for intravenous infusion.

5 tion by either intramuscular autoinjector or intravenous infusion.

6 bine (100 mg per square meter) by continuous intravenous infusion.

7 /m(2) was administered as a single 60-minute intravenous infusion.

8 ctions, especially when used as a continuous intravenous infusion.

9 d 2,400 mg/m2 administered as a twice weekly intravenous infusion.

10 administered in 28-day cycles by continuous intravenous infusion.

11 an acceptable safety profile after a single intravenous infusion.

12 re capable of homing back to the marrow post-intravenous infusion.

13 ry application of adenosine against standard intravenous infusion.

14 ong preference or if difficulties occur with intravenous infusions.

15 essure (MAP) and heart rate 24 h/day and for intravenous infusions.

16 easured by the Aellig technique during local intravenous infusions (0.1 to 3 nmol/min) of apelin-36,

17 infusion for 3 hrs followed by a continuous intravenous infusion (1 mL/kg/hr) of 5% hypertonic salin

18 ) yields identical FFR results compared with intravenous infusion (140 mug/kg per minute), while requ

19 or 1000 mg (n = 7) dosing arms of rituximab intravenous infusions (500 or 1000 mg), given at study d

20 Rats anesthetized with isoflurane were given intravenous infusions (9 mL/kg over 1 min) of either 20%

21 osertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week or be

22 d anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, an

23 raised plasma fibrinogen levels in mice via intravenous infusion and induced thrombosis by ferric ch

24 tes and nitrates [NOx]) after (15)N-arginine intravenous infusion and on asymmetric dimethylarginine

25 midazolam were independently administered by intravenous infusion and plasma and brain concentrations

26 s are trapped in the lungs immediately after intravenous infusion and their survival time in the host

27 treatment and 11.1% that of daily continuous intravenous infusions and oral valganciclovir compared w

28 mit physiological insight, e.g. the need for intravenous infusions and restriction to short-term stud

29 es have been initiated, including continuous intravenous infusions and subcutaneous IL-15 administrat

30 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or i

31 ), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicat

32 ost-partum haemorrhage, needs refrigeration, intravenous infusion, and skilled providers for optimum

33 which is currently explored by a continuous intravenous infusion approach.

34 Cetuximab was given as a weekly intravenous infusion at 250 mg/m(2) after an initial loa

35 Eculizumab was administered by intravenous infusion at 600 mg every 7 +/- 2 days for 4

36 Patients received romidepsin as an intravenous infusion at a dose of 14 mg/m(2) on days 1,

37 cycles of gemcitabine (1000 mg/m(2), 30 min intravenous infusion, at days 1, 8, and 15) and capecita

38 10 (n=150) or placebo (n=147) as a 30-minute intravenous infusion before surgery.

39 t oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemothera

40 5% confidence interval, 2.7 to 11.3), as did intravenous infusion, but again intracoronary infusion d

41 y by transgenic overexpression or acutely by intravenous infusion caused hypophosphatemia, phosphatur

42 of YM155 administered by 168-hour continuous intravenous infusion (CIVI).

43 Twelve biweekly intravenous infusions containing either pegloticase 8 mg

44 ects, 250 mug/M) or placebo (66 subjects) by intravenous infusion daily for 14 days.

45 ing flavopiridol by a 24- to 72-h continuous intravenous infusion demonstrated no clinical activity.

46 vopiridol concentration and makes continuous intravenous infusion dosing ineffective.

47 blocking agent be administered by continuous intravenous infusion early in the course of acute respir

48 doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks.

49 .6, 0.9, or 1.2 mg/kg brentuximab vedotin by intravenous infusion every 2 weeks with either ABVD (25

50 Avelumab was given as a 1-h intravenous infusion every 2 weeks.

51 b (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) versus placebo plus

52 Pemetrexed was administered as a 10-minute intravenous infusion every 21 days.

53 cetaxel was given at a dose of 75 mg/m(2) by intravenous infusion every 3 weeks for up to six cycles.

54 igned to receive either volasertib 300 mg by intravenous infusion every 3 weeks or an investigator's

55 domly assigned (2:1) to siltuximab (11 mg/kg intravenous infusion every 3 weeks) or placebo; all pati

56 etirinotecan pegol (145 mg/m(2) as a 90-min intravenous infusion every 3 weeks) or single-drug treat

57 reated with brentuximab vedotin 1.8 mg/kg by intravenous infusion every 3 weeks.

58 n every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens

59 mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by

60 lus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h) or best available therap

61 expression received avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed dise

62 se of 20 mug/kg/d administered by continuous intravenous infusion for 10 days resulted in a massive (

63 vention) or saline (control) as a continuous intravenous infusion for 24 h.

64 monotherapy was administered via continuous intravenous infusion for 28 days then tapered to daily i

65 ic saline or 0.9% normal saline in a 8-mL/kg intravenous infusion for 3 hrs followed by a continuous

66 tment included FU 200 mg/m2/d via continuous intravenous infusion for 4 weeks followed by 1 week of r

67 ion administered over 5-20 min or continuous intravenous infusion for 6-96 h on day 1 of every 21-day

68 limumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four d

69 Use was defined as having received an intravenous infusion for any time period during the stay

70 f approximately 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in p

71 s: 1) glucose gavage and 2) hyperinsulinemic intravenous infusion, for studies in either beta-cell sp

72 (1:1) to receive either infliximab (5 mg/kg intravenous infusion given over 2 h at baseline, and aga

73 Zoledronic acid given by intravenous infusion has been widely used, but places a

74 mg/kg/day) was delivered through continuous intravenous infusion, hepatic SAMe levels reached 0.7 mM

75 Intravenous infusion in AKO rats of human amylin, or com

76 ent course; rIL-21 was administered by rapid intravenous infusion in an outpatient setting.

77 ugate of Escherichia coli L-asparaginase, by intravenous infusion in children with ALL.

78 Intravenous infusion in mice resulted in virus replicati

79 h kallikrein activation when administered by intravenous infusion in swine.

80 ned to self-administer cocaine (0.125 mg per intravenous infusion) in a lever-pressing task in a dail

81 es transgene products in cancer tissue after intravenous infusion, in a dose-related fashion.

82 The TERLI group received terlipressin by intravenous infusion, initially 3 mg/24 hours, progressi

83 ers were recovered in heart and kidney after intravenous infusion into mice with myocardial infarcts.

84 vation that IL-15 administered by continuous intravenous infusion is able to induce markedly greater

85 Terlipressin given by continuous intravenous infusion is better tolerated than intravenou

86 travenous bolus followed by a 4-h continuous intravenous infusion, is active in high-risk, refractory

87 PTRA with elamipretide (0.05 mg/kg per hour intravenous infusion, n=6) or placebo (n=8).

88 Intravenous infusion narcotics (fentanyl, morphine, or h

89 Simultaneously, a continuous intravenous infusion of (1)(3)C-leucine and (2)H(5)-phen

90 y candidates, tumor size > 2 cm) received an intravenous infusion of (18)F-fluoropaclitaxel and then

91 clusion and treated with either a continuous intravenous infusion of 0.9% saline or 3% hypertonic sal

92 is the first human study to demonstrate that intravenous infusion of 0.9% saline results in reduction

93 SAP consisted of single-shot, intravenous infusion of 1.5 g of cefuroxime, a commonly

94 compared the safety and efficacy of a single intravenous infusion of 1500 mg of dalbavancin to the 2-

95 al resection by laparotomy received a single intravenous infusion of 185 MBq/10 mg of (124)I-cG250 ov

96 Intravenous infusion of 20 such cells into healthy synge

97 ation, rats were pretreated with either NAc (intravenous infusion of 50 mg/kg/h) or MK-801 (0.16 mg/k

98 Patients received an intravenous infusion of 7.5 mg/kg MABp1 or placebo given

99 After an overnight intravenous infusion of 99% enriched [1-(13)C]glucose to

100 (n = 11) men and women (n = 6) were given an intravenous infusion of [(2)H(2)]palmitic acid to invest

101 es after drug injection, animals received an intravenous infusion of [1,6-(13)C2]glucose for 8 min to

102 asting, eight healthy volunteers received an intravenous infusion of [6,6-(2)H(2)]-glucose.

103 MCE was performed at baseline and after intravenous infusion of acetylcholine or adenosine.

104 In patients with SMA1, a single intravenous infusion of adeno-associated viral vector co

105 c), and 2 FFR measurements during continuous intravenous infusion of adenosine (140 mug/kg per minute

106 Intracoronary saline given on top of an intravenous infusion of adenosine did not further increa

107 A single intravenous infusion of allogeneic, bone marrow-derived

108 optimal medical treatment were randomized to intravenous infusion of allogenic UC-MSCs (Cellistem, Ce

109 erate disease in 6 adult males who underwent intravenous infusion of an adeno-associated viral (AAV)

110 increased blood pressure response to chronic intravenous infusion of ANG II.

111 lysis to compare prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams in

112 The intravenous infusion of apolipoprotein E4 exacerbated th

113 Intravenous infusion of argatroban, a direct thrombin in

114 ited by 44% in LS; however, the simultaneous intravenous infusion of ascorbic acid or apocynin acutel

115 uced by 32% but was restored by simultaneous intravenous infusion of ascorbic acid or apocynin.

116 Participants received intravenous infusion of autologous bone-marrow-derived m

117 m(2)] daily for 5 days, followed by a single intravenous infusion of autologous TILs and high-dose in

118 exercise, acute normobaric hypoxia, and the intravenous infusion of catecholamines, or absent/decrea

119 Intravenous infusion of CD19-targeted nTregs into SCID-B

120 Intravenous infusion of CIK cells delayed autologous tum

121 tion with [(11)C]CUMI-101 after receiving an intravenous infusion of citalopram 10 mg or placebo in a

122 difference in DA signaling is exaggerated by intravenous infusion of cocaine.

123 uglycemic clamps with a physiologic low-dose intravenous infusion of cortisol to reproduce levels fou

124 C-verapamil (30-72 MBq/kg) before and during intravenous infusion of CsA (12 or 24 mg/kg/h, n = 2 eac

125 sed at rest, during low-dose, and after peak intravenous infusion of dobutamine/atropine.

126 Following intravenous infusion of either 0.9% (ISO) or 3.0% (HYPER

127 ls of lithium or valproate received a single intravenous infusion of either ketamine hydrochloride (.

128 c levels of lithium or valproate received an intravenous infusion of either ketamine hydrochloride (0

129 We observed that intravenous infusion of either murine tetrameric hemoglo

130 Specifically, intravenous infusion of either polystyrene or biodegrada

131 acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15

132 EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vinc

133 Intravenous infusion of ex vivo-labeled WT or CCR2(-/-)

134 In study A, subjects received an intravenous infusion of ex9-39 or saline plus an oral gl

135 (days 9 and 10) without and with a high-dose intravenous infusion of exendin [9-39].

136 was followed by two 4-week courses of weekly intravenous infusion of gemcitabine (1000 mg/m2, 3 of 4

137 s, and 141 patients to receive 1000 mg/m2 of intravenous infusion of gemcitabine once a week for 3 of

138 A short (30-min) intravenous infusion of GLP-2 resulted in a marked incre

139 ients undergoing colorectal surgery received intravenous infusion of glucose with amino acids.

140 species, inhaled NO administered before the intravenous infusion of HBOC can prevent systemic vasoco

141 under baseline conditions (n = 4) and during intravenous infusion of high-dose erlotinib (10 mg/kg/h,

142 Intravenous infusion of HYPER saline increased plasma os

143 We examined if intravenous infusion of hyperosmotic saline affects skin

144 tomy for esophageal adenocarcinoma) received intravenous infusion of IdU (200 mg/m(2) body surface ar

145 ral nervous uptake of the IN 210 IU dose via intravenous infusion of ins-asp at a dose of 0.12 IU/kg/

146 After 60 min, intravenous infusion of insulin (15 mU kg-1 min-1), but

147 is hypothesis, a GABA deficit was induced by intravenous infusion of iomazenil (IOM; 3.7 mug/kg), an

148 he 'Iron Protocol' studied the effects of an intravenous infusion of iron on the pulmonary vascular r

149 ts were randomized 1:1:1 to receive a single intravenous infusion of KB001, 3 mg/kg (n=13) or 10 mg/k

150 Intravenous infusion of KCO912 (K(ATP) agonist), minoxid

151 ive Battery (MCCB) before and after a single intravenous infusion of ketamine (0.5 mg/kg) or midazola

152 nderwent MRI at baseline then 24 h following intravenous infusion of ketamine (0.5 mg/kg).

153 le (MADRS) score of >/= 22 received a single intravenous infusion of ketamine (0.5 mg/kg).

154 order patients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg

155 Intravenous infusion of ketamine hydrochloride (0.5 mg/k

156 double-blind conditions to receive a single intravenous infusion of ketamine or midazolam in a 2:1 r

157 ore symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up

158 ptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting u

159 ealthy young male volunteers underwent a 7-h intravenous infusion of l-[ring-(2)H5]phenylalanine on t

160 The first study consisted of a 5-h intravenous infusion of l-carnitine while circulating in

161 In vivo: A single intravenous infusion of lipid-free apoA-I (8 mg/kg) admi

162 le Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1) h(-1)) or

163 ed Sprague-Dawley rats received a continuous intravenous infusion of LPS (15 microg kg(-1) h(-1)), De

164 In this article, we confirm that intravenous infusion of male BMSC reduced the severity o

165 C57BL/6 mice received an intravenous infusion of MBs and either "naked" luciferas

166 The role of an intravenous infusion of Mg alone in facilitating electri

167 mia were not observed in rhesus monkeys when intravenous infusion of MK-3682 was completed after AMIO

168 placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextros

169 g, bolus) on GI motility were studied during intravenous infusion of naloxone hydrochloride or naloxo

170 continuous feeding on two occasions: during intravenous infusion of niacin (2.8 mg/min) and saline.

171 laboratory studies of older smokers based on intravenous infusion of nicotine.

172 nts were randomly assigned 2:1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimuma

173 response system) patients 2:1 to receive an intravenous infusion of nivolumab 3 mg/kg every 2 weeks

174 n ADA-deficient pups received transplants of intravenous infusion of normal congenic bone marrow, wit

175 blinded randomized fashion with a continuous intravenous infusion of normal saline, 3% hypertonic sal

176 These findings were supported in vivo, where intravenous infusion of oleic acid (OA) in mice increase

177 d ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cispl

178 , 34 healthy men received a 6-h double-blind intravenous infusion of omecamtiv mecarbil or placebo on

179 response system, to standard care plus 48-h intravenous infusion of placebo (n=62) or relaxin 10 mic

180 e randomized to receive a double-blind, 48-h intravenous infusion of placebo or OM in 3 sequential, e

181 ulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2

182 tivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m(2) followed by a 3-h

183 Intravenous infusion of protein/peptide Ags linked to sy

184 rticipants with magnetoencephalography after intravenous infusion of psilocybin--prodrug of the nonse

185 Intravenous infusion of recombinant human activated Fact

186 one for 1 month (control) or to add a single intravenous infusion of rituximab (375 mg/m(2); interven

187 x rhesus monkeys were depleted of B cells by intravenous infusion of rituximab (anti-CD20) 28 days an

188 revious randomised controlled phase 2 trial, intravenous infusion of salbutamol for up to 7 days in p

189 rticipants were randomized to receive a 6-hr intravenous infusion of saline (control), an intermediat

190 a neuronal inhibitor, into the DMH prior to intravenous infusion of saline or MDMA in conscious rats

191 s in mean arterial pressure (MAP) induced by intravenous infusion of sodium nitroprusside (SNP) and p

192 oom temperature (22 degrees C) for 4 h or by intravenous infusion of the alpha-adrenergic receptor an

193 vity in 33 individuals who received a single intravenous infusion of the antibody.

194 gether with duodenal nutrition perfusion and intravenous infusion of the glucagon-like peptide 1 (GLP

195 ine Protocol' examined the effects of an 8 h intravenous infusion of the iron chelator desferrioxamin

196 que monkey under control conditions or after intravenous infusion of the NET inhibitor desipramine (D

197 humans were studied before, during a 60 min intravenous infusion of the NOS inhibitor N(G)-nitro-l-a

198 uted tomography (SPECT) images obtained with intravenous infusion of the radioactive tracer Technetiu

199 to discrete pulses of activity revealed that intravenous infusion of the synthetic mixed glucocortico

200 spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses o

201 CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of CD133-positive ha

202 monary hypertension was induced in 8 pigs by intravenous infusion of thromboxane A2 analogue.

203 Evaluate the safety and efficacy of the intravenous infusion of UC-MSC in patients with chronic

204 Intravenous infusion of UC-MSC was safe in this group of

205 on fraction, no clinical trial has evaluated intravenous infusion of UC-MSCs in these patients.

206 urs following no infusion (controls; n=6) or intravenous infusion of ultrasmall superparamagnetic par

207 diac arrest undergoing CPR to either a rapid intravenous infusion of up to 2 L of cold saline or stan

208 cts of 4 weekly subcutaneous injections or 1 intravenous infusion of ustekinumab in 27 patients who w

209 A single intravenous infusion of vector in all 10 patients with s

210 Intravenous infusion of WST11 (4 mg per kilogram of body

211 Intravenous infusion of WT- and Nox2-deficient BMCs into

212 phthalmologist-confirmed AAU occurring after intravenous infusion of zoledronate (5 mg).

213 Intravenous infusion of zoledronate 5 mg or placebo.

214 who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placeb

215 A single 5 mg intravenous infusion of zoledronic acid is non-inferior,

216 nd the USA, tested the effectiveness of 5 mg intravenous infusion of zoledronic acid versus 5 mg oral

217 We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior

218 Intravenous infusions of (13)C-labelled nutrients reveal

219 We compared the effects of intravenous infusions of 0.9% saline ([Cl] 154 mmol/L) a

220 or greater were randomized to 3 once-monthly intravenous infusions of 10 mg/kg GSK679586 (n = 99) or

221 nteractive voice response system, to receive intravenous infusions of 10 mg/kg ipilimumab or placebo

222 to 400 m on 6 MWT, were randomized to weekly intravenous infusions of 30 or 50 mg/kg/wk eteplirsen or

223 cular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m(2) CT-P10 or rituximab

224 c resonance spectroscopy in conjunction with intravenous infusions of [(13)C]glucose in healthy volun

225 onditions and during 4 postprandial hours by intravenous infusions of [3,3,3-(2)H3]-leucine and [ring

226 Overnight fasted adults (n = 61) received intravenous infusions of [U-(13)C]palmitate (0400-0830 h

227 tients with AATD were treated with 12 weekly intravenous infusions of AAT augmentation therapy before

228 andomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicemine 50 mg, la

229 th prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Abeta

230 t desmopressin (1 nmol.kg(-1)) or continuous intravenous infusions of arginine vasopressin (3 pmol.kg

231 efore starting treatment and after 12 weekly intravenous infusions of AVI-4658.

232 atomegaly also occurs when animals are given intravenous infusions of bacterial lipopolysaccharide (L

233 ) patients with cancer who were treated with intravenous infusions of bisphosphonates between January

234 rrent hemophilia treatment involves frequent intravenous infusions of clotting factors, which is asso

235 Rats were trained to lever press for intravenous infusions of cocaine before extinction.

236 eal was used to measure energy intake during intravenous infusions of either PYY(3-36) or oxyntomodul

237 Pregnant ewes received intravenous infusions of ethanol or saline during days 6

238 ntuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24

239 intravenous infusions of placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg

240 in autonomic and respiratory responses after intravenous infusions of hypertonic sodium lactate.

241 Patients were assigned randomly to receive intravenous infusions of infliximab 5 mg/kg at weeks 0,

242 lesions report panic anxiety in response to intravenous infusions of isoproterenol, a beta-adrenergi

243 ) patients were randomized to receive either intravenous infusions of LOLA (n = 98), 30 g daily, or p

244 , experimentally induced asthma received six intravenous infusions of MSCs (0.36-2.5 x 10E7 MSCs/infu

245 Participants received 30 minute intravenous infusions of NKB and vehicle in random order

246 anges in venous oxygenation before and after intravenous infusions of placebo and psilocybin.

247 Multiple sessions including intravenous infusions of placebo or scopolamine hydrobro

248 d by study centre to standard care plus 48-h intravenous infusions of placebo or serelaxin (30 mug/kg

249 or > or = 4 weeks were randomized to receive intravenous infusions of placebo plus MTX or intravenous

250 Patients were assigned to receive intravenous infusions of RRx-001 at increasing doses (10

251 uropathic pain)-and a control group received intravenous infusions of saline in an initial session an

252 lve healthy adult male subjects received 1-L intravenous infusions of Voluven or PVR over 30 minutes

253 e or the current standard of care plus three intravenous infusions of ZMapp (50 mg per kilogram of bo

254 However, catheter-based delivery, but not intravenous infusion, of LNA-92a significantly (P<0.05)

255 (2) monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle.

256 Rituximab was given at 375 mg/m(2) as an intravenous infusion on day 1 of each cycle.

257 1 ratio), to receive docetaxel 75 mg/m(2) by intravenous infusion on day 1 plus either nintedanib 200

258 a fixed dose of 15 000 IU/m(2) bleomycin by intravenous infusion on day 4.

259 56 mg/m(2) thereafter) was given as a 30-min intravenous infusion on days 1, 2, 8, 9, 15, and 16 of 2

260 eceived romidepsin at 14 mg/m(2) as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days.

261 days) (n = 551) or gemcitabine (1000 mg/m(2) intravenous infusion once a week for 3 of every 4 weeks)

262 s of deforolimus administered as a 30-minute intravenous infusion once daily for 5 consecutive days e

263 rmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d.

264 APR-246 was administered as a 2-hour intravenous infusion once per day for 4 consecutive days

265 rs were treated with cixutumumab as a 1-hour intravenous infusion once per week.

266 near-constant obsessions received two 40-min intravenous infusions, one of saline and one of ketamine

267 lipressin has been used either as continuous intravenous infusion or as intravenous boluses.

268 ow oral availability and requires continuous intravenous infusion or multiple gram doses to ensure su

269 s infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1.3 mg/m(2); intrav

270 ntravenous bolus on day 1 or 72 h continuous intravenous infusion) or intensified doxorubicin (75 mg/

271 of 900 mg/m(2) was to be administered as an intravenous infusion over 10 minutes every 21 days.

272 ays and 28 mug/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to f

273 m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15

274 AEG35156 was administered by continuous intravenous infusion over 7 days (7DI) or 3 days (3DI) o

275 e plus 16 cycles of 7.5 mg/kg bevacizumab by intravenous infusion over 90 min on day 1 of each cycle.

276 receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 week

277 lve healthy adult male subjects received 2-L intravenous infusions over 1 hour of 0.9% saline or Plas

278 ts) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care includi

279 s compare the efficacy of different forms of intravenous infusion sedation for critically ill patient

280 f mechanically ventilated patients receiving intravenous infusion sedation has increased over time.

281 We sought to describe current use of intravenous infusion sedation in mechanically ventilated

282 Most patients who received intravenous infusion sedation received propofol (82.2%,

283 Imetelstat was administered as a 2-hour intravenous infusion (starting dose, 9.4 mg per kilogram

284 In a double-blind, placebo-controlled intravenous infusion study of ketamine, we measured glut

285 Previously, it had been given by intravenous infusion; such administration is associated

286 ndomly assigned to receive either continuous intravenous infusion (TERLI-INF group) at the initial do

287 on of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD w

288 time to FFR was 100 +/- 27 s for continuous intravenous infusion versus 23 +/- 14 s for intracoronar

289 administration of terlipressin as continuous intravenous infusion versus intravenous boluses in the t

290 Vinflunine 320 mg/m2 by 10-minute intravenous infusion was administered on day 1 of 21-day

291 Dexamethasone (20 mg oral or intravenous infusion) was given on days 1, 2, 8, 9, 15,

292 eceived gemcitabine 1000 mg/m(2) as a 30-min intravenous infusion, weekly, for 7 weeks followed by a

293 Three 52-min intravenous infusions were administered: ketamine (.41 m

294 In study B, intravenous infusions were identical, but an oral mixed-

295 as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion dem

296 Intravenous infusion with IS confirmed the superfusion r

297 Forty-three patients were treated by intravenous infusion with MK-8776 at seven dose levels r

298 f ZEBOV; 11 of these monkeys were treated by intravenous infusion with rhAPC beginning 30-60 min afte

299 each diet, subjects cycled for 60 min after intravenous infusion with saline (CD and HFD) or dichlor

300 travenous bolus followed by a 4-h continuous intravenous infusion would achieve serum concentrations